Interventions
ADVERSE EVENT
Patients initiated treatment with either ADA (40 mg every 14 days) or TOF (10 mg daily) and, in the target trial, would be expected to continue treatment during follow-up unless an adverse event or contraindication occurred. The limited duration of availability of the biosimilar for ADA meant that all ADA interventions were the originator and not the biosimilar.